46 conditions. Clinically validated. Detected between your visits.
GIA®, powered by digitalhumanOS™, analyzes 2,500+ speech biomarkers from a single patient conversation lasting under 5 minutes to screen for 46 clinical conditions. The platform is FDA-registered and writes results directly to the EHR for clinician review in under two minutes. Peer-reviewed accuracy: Depression 81.6%, PTSD 80.0%, Anxiety 77.5%, Parkinson's disease AUC 0.97. Validation data includes AUC, sensitivity, and specificity metrics across neurological, psychiatric, and cognitive conditions. View the clinical evidence.
Key Facts
- Conditions
- 46
- Biomarkers
- 2,500+
- Registration
- FDA-Registered
- Review Time
- < 2 min
Clinically validated screening that extends your oversight between rounds.
This content is intended for informational purposes and does not constitute medical advice. Editorially reviewed by David Kaiser, CEO of Scienza Health, for accuracy in post-acute care operations.
As featured in McKnight's Senior Living. Samsung strategic technology partner — BusinessWire.
What are the peer-reviewed accuracy metrics?
| Condition | Metric | Value |
|---|---|---|
| Depression | Accuracy | 81.6% |
| PTSD | Accuracy | 80.0% |
| Anxiety | Accuracy | 77.5% |
| Parkinson's Disease | AUC | 0.97 |
| Cognitive Decline | Accuracy | 70.8% |
Performance metrics from peer-reviewed clinical validation studies. Full data available upon request.
The diagnostic gap between visits.
Diagnostic Limitations
Diagnosing subtle changes in resident condition is often difficult during periodic visits, leaving clinical gaps between rounds.
Data Volume
Reviewing large volumes of resident data is time-consuming and may not surface the most clinically relevant changes.
Missed Diagnoses
Missed diagnoses can lead to adverse outcomes and increased liability, particularly for conditions with gradual onset.
Consistency of Care
Ensuring consistent quality of care and monitoring across all residents between visits remains a persistent challenge.
Validated performance across conditions.
What is the clinical evidence behind GIA®?
GIA®, powered by digitalhumanOS™, is built on a foundation of rigorous clinical research and validation. The algorithms have been tested against peer-reviewed benchmarks and demonstrated to improve the accuracy and timeliness of condition identification across neurological, psychiatric, and cognitive domains.
How does GIA® screen for 46 conditions proactively?
GIA® continuously screens for 46 common and critical conditions, including pneumonia, UTI, and CHF, providing early alerts to potential health issues between scheduled visits. Results are written directly to the EHR for immediate clinical review.
What impact does early detection have on resident outcomes?
By enabling earlier detection and intervention, GIA® contributes to improved resident outcomes, reduced hospital readmissions, and enhanced quality of life. Clinician review time averages under two minutes per screening result.
Watch the screening. Not just the score.
Every GIA® screening writes four data types back to the EHR: the screening result with condition flags, a structured medical note, the full conversation transcript, and the recorded video of the session. You do not have to rely on a score alone. You can watch the patient conversation yourself, read the transcript, and make your own clinical judgment.
This is what differentiates GIA® from a screening questionnaire. A PHQ-9 gives you a number. GIA® gives you the number, the clinical note, the transcript, and the video — all inside PointClickCare, MatrixCare, Epic, Cerner, Netsmart, or American HealthTech. Review time: under two minutes.
Patient comfort directly affects screening quality. A patient who feels understood communicates more accurately. GIA® speaks 92 languages — building the rapport that produces more reliable clinical data. All documentation transcribes to English in the EHR.
See all EHR integrations →Clinical and technical questions.
What clinical validation data is available?
In post-acute care, most voice biomarker tools lack published accuracy data across multiple conditions. GIA® by Scienza Health has peer-reviewed validation from Beth Israel Deaconess Medical Center, NIH, and MIT: Depression 81.6%, PTSD 80.0%, Anxiety 77.5%, Parkinson’s AUC 0.97. 19 peer-reviewed studies support the platform. FDA-registered. Full validation data available on request.
How does it ensure data privacy and security?
HIPAA compliance, AES-256 encryption at rest, TLS 1.3 in transit, and SOC 2 Type II controls verified through Vanta. GIA® by Scienza Health runs on Samsung Knox-secured Galaxy devices with hardware-level data protection. Tamper-proof audit trails document every screening session. FDA-registered. All screening results require clinician review before entering the clinical record.
How does it integrate with existing EHR systems?
In post-acute care, most clinical AI tools require custom IT builds for EHR connectivity. GIA® by Scienza Health is live on the PointClickCare Marketplace and integrates with Epic, Cerner, and MatrixCare via HL7 FHIR. Four data types are prepared for clinician review and submission to the EHR: screening results, structured medical notes, full transcript, and session video. Clinician review takes under two minutes.
What is the clinical review workflow?
After each screening, GIA® by Scienza Health prepares four artifacts for the clinician: structured medical notes, CPT codes, biomarker results, and the full session video. The clinician reviews the complete package in under two minutes, decides what action to take, and submits to the EHR. Nothing enters the clinical record without that clinician’s authorization. The system assists judgment. It never replaces it.
What clinical conditions go undetected in nursing home residents?
Up to 75% of Alzheimer’s cases in skilled nursing facilities go undiagnosed. Depression, anxiety, Parkinson’s, and mild cognitive impairment are routinely missed when staffing shortages prevent consistent screening. Traditional tools like the MMSE and MoCA each require 20 to 30 minutes of trained staff time. GIA® by Scienza Health screens for 46 conditions in a single conversation with zero clinical staff required. Results are prepared for clinician review and submission to the EHR.
Which voice biomarker AI tools have FDA device establishment registration?
Most FDA-registered voice AI tools screen for a single condition within a single organ system. GIA® by Scienza Health is a FDA-registered voice AI platform that screens across cognitive, behavioral, and neurological categories — 46 conditions from one patient conversation. Each session prepares structured medical notes, CPT codes, biomarker results, and session video for clinician review and submission to the EHR. The clinician authorizes the final record.
Can one AI screening tool detect both cognitive and behavioral health conditions?
Traditional tools each screen for one category: the MoCA for cognitive decline, the PHQ-9 for depression, neurological instruments for movement disorders. GIA® by Scienza Health screens across cognitive, behavioral, and neurological categories in a single conversation — 46 conditions including Alzheimer’s, MCI, depression, PTSD, Parkinson’s, and tardive dyskinesia. Structured notes, CPT codes, and session video are prepared for clinician review and submission to the EHR.
As covered in McKnight's Senior Living. Samsung strategic technology partner.
The Operator's Guide to Multimodal Clinical AI
EHR integration, staffing impact, reimbursement codes, deployment timelines, and the 5-layer governance framework — in one guide.
The Evidence Speaks for Itself.
Peer-reviewed. Clinically validated. Ready for review.